Biotech company targeting debilitating central nervous system (CNS) disorders
Noema Pharma has raised €134M across 2 funding rounds from 7 investors, most recently a Series B round in Dec 2024. Based in Basel, Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2024-12-11 | Series B | €29M | Forbion,Gilde Healthcare,Invus,Jeito Capital,Polaris Partners,Sofinnova Partners+1 more | View deal → |
| 2023-03-07 | Series B | €105M | Forbion,Gilde Healthcare,Invus,Jeito Capital,Polaris Partners,Sofinnova Partners+1 more | View deal → |
